FDA Approves First TA-TMA Treatment

Attention. The FDA just approved the first-ever treatment for a deadly stem cell transplant

complication that affects up to 56% of patients. It's called Yartemlea, and it targets TA-TMA,

a condition that damages blood vessels and causes organ failure. Before this,

doctors had zero approved treatments. Now, clinical trials show a 61-68% complete

response rate and 73-74% survival at 100 days. This is massive for both adults

and kids as young as two. For the first time, there's real hope against what used

to be a death sentence.